A look at the drugs approved in 2018. Part 1 includes: Dermatology, Genetic Diseases, and Immunology
A look at the drugs approved in 2018. Part 2 includes: Infectious Disesases, Neurology, and Oncology
A look at the drugs approved in 2018. Part 3 includes: Opthalmology, Pain Management, Respiratory Diseases, and Women's Health
The FDA has declined to approve a drug that aims to treat familial chylomicronemia syndrome, a rare genetic disorder that could cause potentially fatal pancreatitis.
The FDA has approved a new drug combination for the treatment of adults with Waldenström’s macroglobulinemia.
The FDA has updated the prescribing information of 2 cancer immunotherapies to include the requisite use of a companion diagnostic test to determine PD-L1 levels in the tumor tissue of patients with locally advanced or metastatic urothelial cancer.
The FDA has approved a drug for the treatment of patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.
The FDA has approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions in adults and pediatric patients.
The FDA has approved a new treatment for adult patients with peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis.
The FDA has approved an intravenous injection for the treatment of adults with 2 rare types of non-Hodgkin lymphoma.